UBXN11 and prostate cancer: A single-center study involving 271 patients with either initial or prior negative prostate biopsy found that the two-gene panel combined with SOC variables was able to significantly improve the prediction of ≥GGG 2 prostate cancer on subsequent biopsy compared to SOC variables alone (AUC of 0.88 and 0.8, respectively) [54].